Breadcrumb navigation

Newsroom

Welcome to NEC Bio Newsroom! Stay updated on our activities.

Recent Events

CEPI

Mar 12, 2025

Could ‘nanoballs’ help defeat the next pandemic threat? 💡 💉

World Economic Forum in Davos

Jun 30, 2025

Last week, it was indeed a very engaging conference for our team at the World Vaccine Summit in Barcelona, 2024. Thank you for your wonderful enthusiasm during the talk by Kaïdre Bendjama. Glimpses below from the presentation!

ESMO Immuno-Oncology Congress 2024

Dec 16, 2024

World Vaccine Congress Barcelona

Nov 5, 2024

International Neoantigen Summit

Apr 30, 2024

Last week, it was indeed a very engaging conference for our team at the 7th International Neoantigen Summit, 2024, in Amsterdam, Netherlands. True to its theme of supercharging neoantigen-based therapeutics & cancer Vaccines, through optimized neoantigen prediction & streamlined clinical translation for faster approval, we take back with us many insightful conversations and new connections. Thank you to all the delegates for an amazing response to our presentation at the conference.

Latest Press Releases

Apr 3, 2026: Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck CancerNEW
Dec 10, 2025: NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025~ Phase I NECVAX-NEO1 basket trial data confirm its safety and immunogenicity and provide clinical proof-of-concept for the use of this investigational oral bacteria-based DNA vaccine in solid tumor patients~
Nov 28, 2025: JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information~ Development of Shared Neoantigen Cancer Vaccines~
Nov 7, 2025: JFCR and NEC Confirm Research Results for Developing Individualized Neoantigen Cancer Vaccines Using Whole-Genome Data
Nov 5, 2025: New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse
Jun 2, 2025: Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050
Apr 1, 2025: NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Mar 10, 2025: CEPI funds Nagasaki University to develop innovative vaccines using Nanoball platform and NEC's AI
Dec 12, 2024: NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1, an AI-Driven Personalized Oral Cancer Vaccine, at ESMO Immuno-Oncology Congress 2024
Nov 8, 2024: Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Nov 7, 2024: NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting
Oct 31, 2024: NEC Bio to Present Developments in the Oncology Field at the 39th Society of Immunotherapy for Cancer (SITC) Summit, 2024
Aug 8, 2024: NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines
Jun 3, 2024: Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
Apr 10, 2024: Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 8, 2024: NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
Mar 5, 2024: Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Jan 9, 2024: Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Sep 14, 2023: NEC selected by AMED for design of a universal vaccine that is effective against influenza virus strains
Sep 4, 2023: NEC OncoImmunity to Present Developments in the Infectious Diseases at 21st Awaji International Forum on Infection and Immunity, 2023
Aug 21, 2023: Nagasaki University and NEC OncoImmunity Collaborate to Design Universal Vaccines Targeting Tropical Infectious Diseases
Aug 8, 2023: Aichi Cancer Center and NEC Develop an Efficient Method for Identifying Lung Cancer Antigens and Antigen-Specific T Cells
Jul 27, 2023: NEC laboratories advances therapeutic cancer vaccine research with new AI model Attentive Variational Information Bottleneck
Jun 6, 2023: Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Apr 18, 2023: New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
Mar 31, 2023: NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
Mar 15, 2023: NEC and Transgene to present recent developments from TG4050 at the American Association of Cancer Research Conference
Jun 8, 2022: Updated Phase I Data with TG4050 Presented at ASCO 2022
Apr 18, 2022: Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Apr 12, 2022: New Positive Preliminary Phase I Data on TG4050, an individualized therapeutic cancer vaccine jointly developed by NEC and Transgene, was presented at the AACR 2022
Apr 8, 2022: CEPI partners with Japan’s NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine
Mar 8, 2022: NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets
Dec 15, 2021: BostonGene and NEC Announce Global Partnership
Nov 23, 2021: Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Mar 8, 2021: NEC joins the CONNECT landmark public-private initiative for precision cancer medicine
Oct 8, 2020: NEC OncoImmunity AS and Oslo University Hospital team up to develop a diagnostic for COVID-19 using artificial intelligence
Oct 6, 2020: Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
Jul 21, 2020: BostonGene and NEC Collaborate to Analyze Cancer Patients in Clinical Trials
Jul 6, 2020: Aichi Cancer Center and NEC launch joint research on fundamental study aimed at advanced cancer immunotherapy through the fusion of AI and experimental immunology
May 25, 2020: NEC Laboratories Europe announces the start of pre-clinical validation studies for NEC’s AI-driven blueprint design for SARS-CoV-2 vaccine
May 15, 2020: Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
Apr 23, 2020: NEC publishes design blueprints for SARS-CoV-2 vaccines using its Artificial Intelligence technology
Mar 23, 2020: University of the Ryukyus and NEC discover a novel diagnostic biomarker for acute adult T-cell leukemia/lymphoma
- Discovery of elevated levels of soluble tumor necrosis factor receptor 2 -
Jan 7, 2020: Transgene and NEC Start Two Clinical Trials with TG4050,an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Nov 12, 2019: NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
Jul 29, 2019: NEC acquires Norwegian bioinformatics company, OncoImmunity AS
May 27, 2019: NEC initiates AI-driven drug discovery business targeting a business valuation of ¥300 billion by 2025
May 14, 2019: NEC becomes the first Japanese company to join the TESLA consortium’s fight against cancer
Apr 26, 2019: Notice on Partial Amendment to the Articles of Incorporation
Apr 25, 2019: Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC
Oct 30, 2018: NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy

Oct 24, 2024: [Health Awareness] How AI-powered cutting-edge technology is revolutionising vaccine development
Apr 10, 2024: [AACR] Investigational Personalized Vaccine Provides Clinical Benefit for Some Patients with Resected Head and Neck Cancers
Jan 31, 2024: [NEC Stories]NEC's Promise in Preventing Infectious Disease: New Initiatives and the Power of One Team
Jan 14, 2023: [NHK WORLD-JAPAN]Tech firm crunches data for next-gen vaccine
Apr 11, 2022: [biopharma dealmakers] NEC: harnessing artificial intelligence-powered drug development to provide tailored medicines
Feb 26, 2021: [NEC Technical Journal] Development of Neoantigen — Targeted Cancer Vaccine Therapy
Jan 8, 2019: [Scrip] NEC Moves Beyond IT Tools As It Pursues AI-Driven Drug Discovery Initiative

Explore our newest technological breakthroughs and uncover NEC Bio's pioneering approach to AI-powered drug development

Recent Publications

NEC Bio B.V.

Breadcrumb navigation

Newsroom

Recent Events

Latest Press Releases

In the News

Explore our newest technological breakthroughs and uncover NEC Bio's pioneering approach to AI-powered drug development